<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vsp</journal-id><journal-title-group><journal-title xml:lang="ru">Вопросы современной педиатрии</journal-title><trans-title-group xml:lang="en"><trans-title>Current Pediatrics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-5527</issn><issn pub-type="epub">1682-5535</issn><publisher><publisher-name>Издательство «ПедиатрЪ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15690/vsp.v12i5.802</article-id><article-id custom-type="elpub" pub-id-type="custom">vsp-284</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБМЕН ОПЫТОМ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXCHANGE OF EXPERIENCE</subject></subj-group></article-categories><title-group><article-title>АТОПИЧЕСКИЙ ДЕРМАТИТ: НОВОЕ В ЛЕЧЕНИИ</article-title><trans-title-group xml:lang="en"><trans-title>ATOPIC DERMATITIS: NEW ASPECTS OF TREATMENT</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мачарадзе</surname><given-names>Д. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Macharadze</surname><given-names>D. Sh.</given-names></name></name-alternatives><bio xml:lang="en"><p>Macharadze Dali Shotaevna, Doctor of Medical Sciences, Professor of the Department of Allergy and Clinical Immunology</p></bio><email xlink:type="simple">dalim_a@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский университет дружбы народов, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>People’s Friendship University of Russia, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>19</day><month>09</month><year>2013</year></pub-date><volume>12</volume><issue>5</issue><issue-title>Вопросы современной педиатрии</issue-title><fpage>80</fpage><lpage>85</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мачарадзе Д.Ш., 2013</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="ru">Мачарадзе Д.Ш.</copyright-holder><copyright-holder xml:lang="en">Macharadze D.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vsp.spr-journal.ru/jour/article/view/284">https://vsp.spr-journal.ru/jour/article/view/284</self-uri><abstract/><trans-abstract xml:lang="en"><p>Atopic dermatitis is a chronic inflammatory cutaneous disease, which demands a prolonged treatment. A modern views on the main approaches to treatment of atopic dermatitis in children and adults are analyzed in this article. The treatment is based on the permanent use of emollients in order to achieve an anti-inflammatory effect — topical calcineurin inhibitors (tacrolimus and pimecrolimus), and short courses (5 days) of topical corticosteroids during relapses. For the 10-year period of topical calcineurin inhibitors usage in treatment of atopic dermatitis a great amount of experimental and clinical data have been accumulated. Two the most important changes and additions in the treatment of atopic dermatitis in recent times were related to a new hypothesis of proactive therapy with the use of topical tacrolimus and closing of «black box» warnings, associated to malignization risk due to the long-term usage of topical calcineurin inhibitors. Since atopic dermatitis is characterized by relapsing course, nowadays topical tacrolimus should be considered the most appropriate treatment approach, both in adults and children. The results of investigations confirmed more than 6-times decrease in relapse rate, as well as the significant improvement of quality of life, when the above-mentioned treatment scheme is used, both in children and adults.</p><p>Key words: children, atopic dermatitis, emollients, treatment, tacrolimus.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>дети</kwd><kwd>атопический дерматит</kwd><kwd>эмоленты</kwd><kwd>терапия</kwd><kwd>такролимус</kwd></kwd-group><kwd-group xml:lang="en"><kwd>children</kwd><kwd>atopic dermatitis</kwd><kwd>emollients</kwd><kwd>treatment</kwd><kwd>tacrolimus</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Saavedra J., Boguniewicz M., Chamlin S., Lake A., Nedorost S., Czerkies L., Patel V., Botteman M., Horodniceanu E. Patterns of clinical management of atopic dermatitis in infants and toddlers: A survey of three physician specialities in the United States. J. Pediatr. 2013; 14: 168–171.</mixed-citation><mixed-citation xml:lang="en">Saavedra J., Boguniewicz M., Chamlin S., Lake A., Nedorost S., Czerkies L., Patel V., Botteman M., Horodniceanu E. Patterns of clinical management of atopic dermatitis in infants and toddlers: A survey of three physician specialities in the United States. J. Pediatr. 2013; 14: 168–171.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kapoor R., Menon C., Hoffstad O., Bilker W., Leclerc P., Margolis D. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J. Am. Acad. Dermatol. 2008; 9: 68–73.</mixed-citation><mixed-citation xml:lang="en">Kapoor R., Menon C., Hoffstad O., Bilker W., Leclerc P., Margolis D. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J. Am. Acad. Dermatol. 2008; 9: 68–73.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Leung D., Nicklas R., Li J., Bernstein I., Blessing-Moore J., Boguniewicz M., Chapman J., Khan D., Lang D., Lee R., Portnoy J., Schuller D., Spector S., Tilles S. Disease management of atopic derma titis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann. Allergy Asthma Immunol. 2004; 9 (Suppl. 2): 1–21.</mixed-citation><mixed-citation xml:lang="en">Leung D., Nicklas R., Li J., Bernstein I., Blessing-Moore J., Boguniewicz M., Chapman J., Khan D., Lang D., Lee R., Portnoy J., Schuller D., Spector S., Tilles S. Disease management of atopic derma titis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann. Allergy Asthma Immunol. 2004; 9 (Suppl. 2): 1–21.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Macharadze D.Sh. Atopicheskiy Dermatit: Sovremennye Metody Diagnostiki i Terapii. Uchebno-Metodicheskoe Posobie [Atopic Dermatitis: Modern Methods of Diagnosis and Therapy. A Teaching Manual]. Moscow, RPK “Liniya-Print” Publ., 2011. 75 p.</mixed-citation><mixed-citation xml:lang="en">Macharadze D.Sh. Atopicheskiy Dermatit: Sovremennye Metody Diagnostiki i Terapii. Uchebno-Metodicheskoe Posobie [Atopic Dermatitis: Modern Methods of Diagnosis and Therapy. A Teaching Manual]. Moscow, RPK “Liniya-Print” Publ., 2011. 75 p.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Suarez-Farinas M., Dhingra N., Gittler J., Shemer A., Cardinale I., de Guzman Strong K., Krueger J., Guttman-Yassky E. Intrinsic atopic dermatitis shows similar Th2 and higher Th17 immune activation compared with extrinsic atopic dermatitis. J. Allergy Clin. Immunol. 2013; 132: 361–370.</mixed-citation><mixed-citation xml:lang="en">Suarez-Farinas M., Dhingra N., Gittler J., Shemer A., Cardinale I., de Guzman Strong K., Krueger J., Guttman-Yassky E. Intrinsic atopic dermatitis shows similar Th2 and higher Th17 immune activation compared with extrinsic atopic dermatitis. J. Allergy Clin. Immunol. 2013; 132: 361–370.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Segal A., Ellis А., Kim H. CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy Asthma Clin. Immunol. 2013; 9 (1): 24–29.</mixed-citation><mixed-citation xml:lang="en">Segal A., Ellis А., Kim H. CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy Asthma Clin. Immunol. 2013; 9 (1): 24–29.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Fleischer A., Boguniewicz M. An approach to pruritus in atopic dermatitis: A critical systematic review of the tacrolimus ointment literature. J. Drugs Dermatol. 2010; 9: 488–498.</mixed-citation><mixed-citation xml:lang="en">Fleischer A., Boguniewicz M. An approach to pruritus in atopic dermatitis: A critical systematic review of the tacrolimus ointment literature. J. Drugs Dermatol. 2010; 9: 488–498.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Meingassner J., Aschauer H., Stuetz A. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroidpretreated skin. Exp. Dermatol. 2005; 14: 752–757.</mixed-citation><mixed-citation xml:lang="en">Meingassner J., Aschauer H., Stuetz A. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroidpretreated skin. Exp. Dermatol. 2005; 14: 752–757.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">McCollum A., Paik A., Eichenfield L. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatr. Dermatol. 2010; 9: 425–436.</mixed-citation><mixed-citation xml:lang="en">McCollum A., Paik A., Eichenfield L. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatr. Dermatol. 2010; 9: 425–436.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Svensson A., Chambers C., Ganemo A., Mitchell S. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr. Med. Res. Opin. 2011; 12: 1385–1406.</mixed-citation><mixed-citation xml:lang="en">Svensson A., Chambers C., Ganemo A., Mitchell S. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr. Med. Res. Opin. 2011; 12: 1385–1406.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Healy E., Bentley A., Fidler C., Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U. K. National Health Service) perspective. Brit. J. Dermatol. 2011; 164: 387–395.</mixed-citation><mixed-citation xml:lang="en">Healy E., Bentley A., Fidler C., Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U. K. National Health Service) perspective. Brit. J. Dermatol. 2011; 164: 387–395.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tennis P., Gelfand J., Rothman K. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Brit. J. Dermatol. 2011; 165: 465–473.</mixed-citation><mixed-citation xml:lang="en">Tennis P., Gelfand J., Rothman K. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Brit. J. Dermatol. 2011; 165: 465–473.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Miyagaki T., Sugaya M. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. J. Dermatol. Sci. 2011; 64: 1–6.</mixed-citation><mixed-citation xml:lang="en">Miyagaki T., Sugaya M. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. J. Dermatol. Sci. 2011; 64: 1–6.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Siegfried E., Jaworski J., Hebert A. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am. J. Clin. Dermatol. 2013; 14: 163–178.</mixed-citation><mixed-citation xml:lang="en">Siegfried E., Jaworski J., Hebert A. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am. J. Clin. Dermatol. 2013; 14: 163–178.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mandelin J., Remitz A., Reitamo S. Effect of oral acetylsalicylic acid on burning caused by tacrolimus ointment in patients with atopic dermatitis. Arch. Dermatol. 2010; 146: 10.</mixed-citation><mixed-citation xml:lang="en">Mandelin J., Remitz A., Reitamo S. Effect of oral acetylsalicylic acid on burning caused by tacrolimus ointment in patients with atopic dermatitis. Arch. Dermatol. 2010; 146: 10.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
